- Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
- Hofseth Biocare ASA: Annual General Meeting completed
- Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
- Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
- Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
- Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
- Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
- Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
More ▼
Key statistics
On Thursday, Hofseth Biocare ASA (HBC:OSL) closed at 2.03, 6.84% above its 52-week low of 1.90, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.10 |
---|---|
High | 2.15 |
Low | 2.00 |
Bid | 2.00 |
Offer | 2.25 |
Previous close | 2.23 |
Average volume | 119.27k |
---|---|
Shares outstanding | 395.08m |
Free float | 165.07m |
P/E (TTM) | -- |
Market cap | 821.77m NOK |
EPS (TTM) | -0.270 NOK |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼